The withdrawal of the F-1 is a bearish signal for a micro-cap biotech—abandoned capital raise suggests weak demand or adverse terms. Monitor for alternative financing (debt, private placement) or cash runway updates in the next 20-F. The stock may face selling pressure as the market prices in higher dilution risk from future emergency financing.
Price Chart
Executive Summary
Regentis Biomaterials withdrew its Form F-1 registration statement for a public offering, effective June 15, 2026, and has decided not to pursue the offering. This removes immediate dilution risk but also signals the company abandoned a capital-raising effort, which is a negative signal for a micro-cap company with an $8M market cap.
Key Facts
- Withdrew Registration Statement No. 333-295510 on Form F-1 effective June 15, 2026.
- Company determined not to pursue the public offering to which the Registration Statement relates.
- Filing signed by CFO Ori Gon on June 15, 2026.
- Market cap is $8M, indicating a micro-cap company with likely limited access to alternative financing.
Financial Impact
Withdrawn F-1 offering of undisclosed size; no capital raised. The company foregoes potential proceeds, increasing cash runway risk.
Risk Factors
- Cash runway may be insufficient without the offering, increasing risk of dilutive financing at distressed levels.
- Abandoned offering could signal lack of investor confidence or unfavorable market conditions for the company.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-068601 |
| Document: 0001213900-26-068601-index-headers.html | 0001213900-26-068601 |
| Document: 0001213900-26-068601-index.html | 0001213900-26-068601 |
| Document: 0001213900-26-068601.txt | 0001213900-26-068601 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $1.63 | awaiting T+20 | — | $1.26 (−22.46%) |
Sep 23, 2026 4w ago | EFFECT | $2.10 $1.49 | ▼ −29.05% | ▼ −29.74% | $1.26 (−40.00%) |
Jul 20, 2026 14w ago | 6-K | $2.00 $2.04 | ▲ +2.00% | ▼ −2.12% | $1.26 (−37.00%) |
Jul 15, 2026 14w ago | 6-K | $2.43 $1.94 | ▼ −20.16% | ▼ −22.51% | $1.26 (−48.15%) |
Jul 14, 2026 14w ago | EFFECT | $2.54 $1.84 | ▼ −27.56% | ▼ −30.05% | $1.26 (−50.39%) |
Jun 15, 2026 19w ago | 6-K | $9.40 $2.43 | ▲ +74.15% | ▲ +74.15% | $1.26 (+86.60%) |
Jun 9, 2026 19w ago | F-1/A | $2.41 $3.64 | ▲ +51.04% | ▲ +49.59% | $1.26 (−47.72%) |
Jun 8, 2026 20w ago | 6-K | $1.28 $3.58 | ▲ +179.69% | ▲ +178.85% | $1.26 (−1.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers